Last reviewed · How we verify

NCT05566704

Retrospective Modulus ALIF Study

Completed Last updated 22 December 2025
What this trial tests

trial testing Modulus ALIF System in Degenerative Disc Disease in 123 participants. Completed in 1 May 2024.

Timeline
18 August 2022
Primary endpoint
15 October 2022
1 May 2024

Quick facts

Lead sponsorNuVasive
StatusCompleted
Study typeOBSERVATIONAL
Enrollment123
Start date18 August 2022
Primary completion15 October 2022
Estimated completion1 May 2024
Sites5 locations across United States

Drugs / interventions tested

Conditions studied

Sponsor

NuVasive — full company profile →

Who can join

18 and older, any sex, with Degenerative Disc Disease or Spondylolisthesis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The primary objective of this study is to evaluate the safety and performance of the Modulus ALIF System in patients undergoing anterior lumbar interbody fusion (ALIF) as measured by reported complications, radiographic outcomes, and patient-reported outcomes.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Degenerative Disc Disease

Currently open trials in the same condition.

Other NuVasive trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05566704.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing